Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Galera Therapeutics, Inc. (GRTX)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
08/14/2023
8-K
Quarterly results
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
",
"
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
"
08/10/2023
8-K
Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce...
Docs:
"
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
"
05/11/2023
8-K
Quarterly results
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
",
"
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
"
03/10/2023
8-K
Regulation FD Disclosure Interactive Data
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
"
03/08/2023
8-K
Quarterly results
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
",
"
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
"
01/25/2023
8-K
Other Events Interactive Data
12/12/2022
8-K
Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data
Docs:
"
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
"
12/09/2022
8-K
Quarterly results
11/09/2022
8-K
Quarterly results
10/26/2022
8-K
Quarterly results
08/09/2022
8-K
Quarterly results
06/16/2022
8-K
Quarterly results
06/10/2022
8-K
Quarterly results
05/16/2022
8-K
Quarterly results
03/10/2022
8-K
Quarterly results
12/14/2021
8-K
Quarterly results
11/10/2021
8-K
Quarterly results
Docs:
"
Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem in combination with SBRT in patients with NSCLC and Pancreatic Cancer; initial data from GRECO-1 expected in 1H2022 Strong cash position of $89M with expected cash runway into 2023 MALVERN, Pa. – November 10, 2021 – Galera Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2021 and provided recent...
"
10/19/2021
8-K
Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
",
"
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis
"
09/08/2021
8-K
Quarterly results
08/18/2021
8-K
Quarterly results
08/10/2021
8-K
Quarterly results
06/17/2021
8-K
Quarterly results
05/11/2021
8-K
Quarterly results
04/28/2021
8-K
Quarterly results
03/11/2021
8-K
Quarterly results
01/06/2021
8-K
Investor presentation
Docs:
"
Corporate Slide Presentation of Galera Therapeutics, Inc.
",
"
Corporate Slide Presentation of Galera Therapeutics, Inc.
"
11/10/2020
8-K
Investor presentation, Quarterly results
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : November 10, 2020 GALERA THERAPEUTICS, INC. Delaware 001-39114 46-1454898 2 W. Liberty Blvd #100 Malvern, PA 19355 725-1500 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exch...
",
"
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
",
"
Corporate Slide Presentation of Galera Therapeutics, Inc.
"
09/25/2020
8-K
Quarterly results
09/16/2020
8-K
Investor presentation
Docs:
"
Corporate Slide Presentation of Galera Therapeutics, Inc.
"
08/10/2020
8-K
Quarterly results
07/14/2020
8-K
Quarterly results
06/10/2020
8-K
Submission of Matters to a Vote of Security Holders
Docs:
"
FORM 8-K
"
05/12/2020
8-K
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
05/12/2020
8-K
Investor presentation, Quarterly results
Docs:
"
FORM 8-K
",
"
Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
",
"
Corporate Slide Presentation of Galera Therapeutics, Inc. dated May 2020
"
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy